HOME >> BIOLOGY >> NEWS
Fighting diabetes: UD researchers move closer to chip-based control of 'smart,' implantable insulin pumps

injections, Parker says. In clinical trials, meanwhile, some 600 diabetic patients worldwide are using MiniMed Technologies' revolutionary implantable pump, which has not yet been approved by the U.S. Food and Drug Administration (FDA).

Compared to frequent insulin injections, Doyle says, pumps seem to provide patients with improved control of their blood-sugar levels, so that they're less vulnerable to diabetes-related health problems.

Smart pumps on the horizon?

But, existing implantable designs simply deliver a low dose of insulin on a continuous basis, Parker notes. Patients also can self-administer additional insulin before a meal.

"By developing glucose sensors and predictive algorithms for these devices," Parker says, "we hope to dramatically improve and automate the control of blood-sugar levels."

Highly precise control is important because sugar concentrations above the normal level of 70 to 120 milligrams of glucose per deciliter of blood (mg/dl) have been associated with liver damage, blindness and other medical problems. And, cells begin to starve when blood-sugar levels fall too low.

So, UD researchers are working on "a smarter brain for the next generation of implantable insulin pumps," Doyle says. "In the future, our system could fit on a computer chip, processing glucose sensor information, and then translating that data into pump action."

Predicting the body's insulin needs

Traditionally, mathematical commands or algorithms for controlling blood-sugar levels have been "like a thermostat-either on or off," Doyle says. "The classic approach has been a bang-bang type of algorithm," he added. "When sugar levels are high, these systems deliver a dose of insulin. When sugar is low, they turn insulin delivery back down."

Unfortunately, this approach isn't "meal-proof," Doyle says, and it doesn't reflect dramatic variations among individuals. In other words, "These algorithms can't predict and plan ahead for the increase
'"/>

Contact: Ginger Pinholster
gingpin@udel.edu
302-831-6408
University of Delaware
6-Jun-1999


Page: 1 2 3

Related biology news :

1. Fighting Mycobacterium tuberculosis with structural proteomics
2. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
3. Fighting the spread of sudden oak death
4. Fighting the battle of the bulge in children
5. Fighting breast cancer at the molecular level
6. Fighting Fungi
7. Fighting skin cancers with computers and technology
8. Trash From Crop-Processing Plant Harvested For Disease-Fighting Agents
9. Studies At Cedars-Sinai Confirm Identity Of An Elusive Receptor In Human Cells -- A Breakthrough In Understanding, Fighting Septic Shock
10. Chemical Contaminants May Inhibit Cancer-Fighting White Blood Cells
11. Radioactive Beads Latest Weapon In Fighting Cancer In Dogs, Cats

Post Your Comments:
(Date:10/29/2014)... who lose their hair as a consequence of chemotherapy ... improve the scalp cooling technology that prevents hair loss. ... being pioneered by global scalp cooling manufacturing company, Paxman ... biology department of the University of Huddersfield. , The ... who has a background in the pharmacology of cancer ...
(Date:10/29/2014)... research presented at the Society for Integrative Oncology ... for the first time that it is possible ... readily available nutritional supplement, AHCC. ... Smith, Pharm.D., associate professor in the Department of ... of Texas Health Science Center at Houston (UTHealth) ...
(Date:10/29/2014)... Many factors, both genetic and environmental, have been ... of schizophrenia. Some, such as a family history ... infection with Toxoplasma gondii , a parasite ... are still viewed with skepticism. , A new ... and epidemiology at the University of Pennsylvania,s School ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
(Date:10/27/2014)... Orlando, Florida (PRWEB) October 27, 2014 ... aims at reducing and eliminating several types of ... have not been achieved in over 30 years ... of Noah's Light Foundation, proves that one mom's ... was diagnosed just before Halloween trick-or-treating, and it’s ...
(Date:10/27/2014)... October 27, 2014 Investor-Edge has ... (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ), ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,483.72, up 0.69%, the Dow Jones ...
(Date:10/25/2014)... 2014 ViaDerma, Inc ... devoted to bringing new products to market, is ... ViaDerma has developed an innovative, patent-pending dual carrier ... transfer of pharmaceutical active ingredients to penetrate the ... localized therapy. The transdermal delivery method also overcomes ...
Breaking Biology Technology:Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
Cached News: